Lamotrigine in Treatment of 120 Children with Epilepsy

Summary: One hundred twenty children aged 10 months to 16 years 9 months were included in three studies with lamotrigine (LTG): a single‐blind study (n = 60), a pharmacokinetic study (n = 23), and a compassionate group (n = 37). At 3 months, 11 patients had become seizure‐free and 34 had >50% decrease in seizure frequency. The best results involved absence epilepsy, Lennox‐Gastaut syndrome (LGS), and other symptomatic generalized epilepsy. Forty‐two patients were followed > 1 year, 22 for a mean of 2.2 years, and there was no significant increase in seizure frequency as compared with 3‐month follow‐up. Fourteen patients became seizure‐free for >6 months; all except 1 had generalized epilepsy. For 12 patients, treatment could be reduced to monotherapy, but for those with valproate (VPA) comedication LTG dosage had to be increased; 25% of patients with VPA monotherapy exhibited skin rash, appearing 3–18 days after starting LTG. For 4 patients, LTG could be reintroduced after VPA was withdrawn. Ten patients had ataxia and/or drowsiness and 2 had vomiting. For all other patients, tolerance was excellent.

[1]  E. Perucca,et al.  Interaction of lamotrigine with sodium valproate , 1993, The Lancet.

[2]  T. Betts.  Clinical use of lamotrigine , 1992, Seizure.

[3]  O. Dulac,et al.  Therapeutic Trial of Vigabatrin in Refractory Infantile Spasms , 1991, Journal of child neurology.

[4]  P. Loiseau,et al.  Workshop on Antiepileptic Drug Trials in Children , 1991, Epilepsia.

[5]  A. Yasuhara,et al.  Epilepsy with Continuous Spike‐Waves During Slow Sleep and Its Treatment , 1991, Epilepsia.

[6]  C. Lahoz,et al.  Benign Myoclonic Epilepsy of Infancy , 1990, Acta paediatrica Scandinavica.

[7]  P. Loiseau,et al.  A randomised double-blind placebo-controlled crossover add-on trial of lamotrigine in patients with treatment-resistant partial seizures , 1990, Epilepsy Research.

[8]  Josemir W Sander,et al.  A randomized double-blind placebo-controlled add-on trial of lamotrigine in patients with severe epilepsy , 1990, Epilepsy Research.

[9]  C. Binnie,et al.  Double-blind crossover trial of lamotrigine (Lamictal) as add-on therapy in intractable epilepsy , 1989, Epilepsy Research.

[10]  T. Kurashige,et al.  Proposal for Revised Classification of Epilepsies and Epileptic Syndromes , 1989, No to hattatsu = Brain and development.

[11]  J. Swann,et al.  Treatment of infantile spasms with high‐dose ACTH , 1989, Neurology.

[12]  G. Goodwin,et al.  Controlled Trial of Lamotrigine (Lamictar) for Refractory Partial Seizures , 1989, Epilepsia.

[13]  J. Dean,et al.  Valproate monotherapy in partial seizures. , 1988, The American journal of medicine.

[14]  D. Hurst.  Severe myoclonic epilepsy of infancy. , 1987, Pediatric neurology.

[15]  O. Dulac,et al.  Sodium valproate monotherapy in childhood epilepsy , 1986, Brain and Development.

[16]  M. Leach,et al.  Pharmacological Studies on Lamotrigine, A Novel Potential Antiepileptic Drug , 1986, Epilepsia.

[17]  A. Depaulis,et al.  A Model of Chronic Spontaneous Petit Mal‐like Seizures in the Rat: Comparison with Pentylenetetrazol‐Induced Seizures , 1984, Epilepsia.

[18]  P. Wolf.  Lamotrigine: Preliminary clinical observations on pharmacokinetics and interactions with traditional antiepileptic drugs , 1992 .

[19]  G. Schapel.  No effect of lamotrigine on carbamazepine and carbamazepine-epoxide concentrations , 1991 .